U.S. markets close in 2 hours 14 minutes

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
47.83+0.14 (+0.28%)
As of 1:45PM EDT. Market open.

Halozyme Therapeutics, Inc.

11388 Sorrento Valley Road
San Diego, CA 92121
United States
858 794 8889
http://www.halozyme.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees136

Key Executives

NameTitlePayExercisedYear Born
Dr. Helen I. TorleyPres, CEO & Director1.52M1.3M1963
Ms. Elaine D. SunSr. VP & CFO859.58kN/A1972
Dr. Michael J. LaBarreSr. VP & Chief Technical Officer710.18k681.37k1964
Mr. Masaru Matsuda Esq.Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.707.84kN/A1971
Mr. Ed GemoVP, Chief Information & Security OfficerN/AN/AN/A
Mr. Albert S. KildaniVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Amy Marinne FoxVP of HRN/AN/AN/A
Mr. William J. FallonSr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic AlliancesN/AN/A1957
Dr. Steve KnowlesChief Medical OfficerN/AN/AN/A
Mr. Todd ButlerChief of Staff to the CEO, VP & Head of Project ManagementN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Halozyme Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 2. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 5; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.